spacer
home > ebr > autumn 2018 > editors letter
PUBLICATIONS
European Biopharmaceutical Review

Editors Letter

Fewer than 10 advanced therapy medicinal products (ATMPs) are currently licensed for use in Europe. The R&D pipeline of early stage ATMP candidates is strong at present, but the manifold challenges (including chemistry, manufacturing and controls, clinical trials, and complex regulatory pathways) to bringing these potentially transformational therapies to market are such that it will take considerable time before their full potential in healthcare is realised. In this autumn 2018 edition of EBR, The Christie Hospital’s Dr Fiona Thistlethwaite and Aptus Clinical’s Dr Ian Thomas introduce the Innovate UK-funded iMatch consortium of clinical and commercial researchers, who will aim to overcome some of the key barriers to successful progression of ATMPs and their scale-up for a range of chronic debilitating conditions (page 14). A major therapeutic focus of ATMP development is oncology, spearheaded by the recently approved Kymriah, for acute B-cell lymphoblastic lymphoma, and Yescarta, for non-Hodgkin lymphoma, from Novartis and Kite/ Gilead respectively. These classes of drug are one of the precision therapies included in N-of-One’s Dr Kathryn D Bungartz’s comprehensive summary of the current cancer therapy innovation landscape (page 56). So too are antibody-drug conjugates, the challenges in production of which and the potential means to circumvent are discussed by the Sanofi and Merck Group teams (page 80).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharmaceutical Packaging and Labelling Summit in Zurich; ACG presentation

At next week’s Pharmaceutical Packaging and Labelling Summit in Zurich (18-19 June), Dr. Eugen Hertel from ACG will be speaking on: Challenges for Global Pharma companies to Implement Anti-Counterfeit Strategy for Russian Track & Trace Regulation. This presentation will include details around ‘the fight against counterfeit medicine - there have been and still are worldwide initiatives to make the supply chain and the safety of medicines secure. After large markets such as the USA and Europe passed their laws and regulations for the pharmaceutical manufacturing companies and established the IT infrastructure, Russia is now next on the move.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement